Greece to probe drug shortages; U.K. fingers brand-favoring physicians;

Drug bottle

@FiercePharma: AbbVie is pharma's first birth of the new year. Story | Follow @FiercePharma

> Greece's top prosecutor has called for an investigation into claims that drugmakers may have deliberately created shortages in the country. Report

> The U.K.'s National Health Service is targeting "inefficient" doctors who prescribe branded drugs rather than generics. Report

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Aurobindo Pharma won final FDA approval to market its version of Merck's ($MRK) Maxalt drug for migraine. Report

> A federal appeals court temporarily barred the U.S. government from forcing an Illinois company to offer insurance coverage for contraceptives. Report

> Pakistani drugmakers will not use active pharmaceutical ingredients imported from India amid a government investigation. Report

> California-based Victory Pharma will pay $11.4 million to resolve a kickbacks probe. Report

Medical Device News

 @FierceMedDev: Diabetes light Dx begins U.S. trial. Story | Follow @FierceMedDev

@MarkHFierce: Dune Medical won an FDA nod for a new tool designed to find cancerous tissue. The company is a rumored M&A target. Report | Follow @MarkHFierce

 @DamianFierce: DJO Global scoops up Minnesota maker of heat-sensitive casts. More | Follow @DamianFierce

> FDA confronts Mindray over patient monitor quality control. News

> Quest Diagnostics slims down for the new year. Story

Biotech News

 @FierceBiotech: Preclinical breast cancer finding could change tamoxifen use. Story | Follow @FierceBiotech

@JohnCFierce: It's official. 39 new drugs approved in 2012, highest since 1996. Big step in the right direction. More | Follow @JohnCFierce

@RyanMFierce: Qualcomm backs clinical trials software outfit in $12M round. News | Follow @RyanMFierce

> AbbVie celebrates New Year's Day as a big new biopharma player. Report

> New cancer drugs help spur drug approvals to 16-year high. Story

CRO News

> India group wants change in clinical trial regs for children. Report

> WuXi, PRA plan to launch joint venture in China. News

> Chinese CRO ShangPharma looks to go private. Article

> goBalto rakes in $12M for cloud-based clinical development. Story

Biotech IT News

> Interview: Stanford's Butte on bridging gap from Big Data to biotech discoveries. Item

> iPad app garners kudos for boosting lab productivity. Article

> iPad app garners kudos for boosting lab productivity. News

> Qualcomm backs clinical trials software outfit in $12M round. Story

Biotech Research News

> Preclinical breast cancer finding could change tamoxifen use. Item

> Enzyme inhibitor could be key to treating malaria. Report

> Scripps drug reduces, reverses fatty liver disease. News

> Chemo combo shows promise against glioblastoma. Article

> Stem cells step forward in ALS. Story

Drug Delivery News

> Radius, 3M update transdermal osteoporosis treatment agreement. News

> Arrowhead polymers boost siRNA delivery 500 times. Story

> Japan welcomes Neupro patch for restless legs and Parkinson's. Article

> QLT signs eye delivery tech option deal with former CEO. Report

> AstraZeneca hitches cancer drug hopes to CytImmune's nano-gold standard. Item

And Finally... Energy drinks are "caffeine delivery systems," rather than unique performance-enhancers, experts say. Report (sub. req.)


Suggested Articles

Late-stage ovarian cancer patients have few options, but now the FDA is reviewing GSK's Zejula for the patient group.

The FDA has raised questions about the manufacturing of Glenmark's new molecular entity Ryaltris, a nasal spray for seasonal allergic rhinitis.

Despite unconventional support from President Donald Trump, Johnson & Johnson’s Spravato didn’t win broad backing at the VA.